利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.027 秒)

    FLUORESCENT SILICA-BASED NANOPARTICLES
    2.
    发明公开
    FLUORESCENT SILICA-BASED NANOPARTICLES 审中-公开
    荧光硅基纳米粒子

    公开(公告)号：EP3223013A1

    公开(公告)日：2017-09-27

    申请号：EP17165118.5

    申请日：2010-07-02

    申请人： Sloan-Kettering Institute for Cancer Research ,  Cornell University

    发明人： BRADBURY, Michelle S. ,  WIESNER, Ulrich ,  PENATE, Medina Oula ,  OW, Hooisweng ,  BURNS, Andrew ,  LEWIS, Jason ,  LARSON, Steven

    IPC分类号： G01N33/50

    CPC分类号： A61K51/1244 ,  A61K9/5115 ,  A61K9/5146 ,  A61K9/5169 ,  A61K49/0019 ,  A61K49/0032 ,  A61K49/0054 ,  A61K49/0056 ,  A61K49/0093 ,  A61K51/08 ,  A61K51/082 ,  A61K51/086 ,  A61K51/1255 ,  B82Y5/00 ,  B82Y15/00 ,  G01N33/54346 ,  G01N33/552 ,  G01N33/574 ,  G01N33/582 ,  G01N33/587 ,  G01N33/60 ,  Y10S977/773 ,  Y10S977/927

    摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

    摘要翻译： 本发明提供了荧光二氧化硅基纳米颗粒，其允许对诸如癌症的疾病的精确检测，表征，监测和治疗。 纳米颗粒具有包括约0.1nm与约100nm之间，约0.5nm与约50nm之间，约1nm与约25nm之间，约1nm与约15nm之间或约1nm与约15nm之间的直径范围 约8nm。 纳米颗粒具有位于纳米颗粒内的荧光化合物，并且具有比游离荧光化合物更高的亮度和荧光量子产率。 纳米颗粒还表现出高生物稳定性和生物相容性。 为了促进纳米颗粒的有效尿排泄，可以用有机聚合物如聚（乙二醇）（PEG）涂覆。 纳米颗粒的小尺寸，二氧化硅基质和有机聚合物涂层使纳米颗粒在体内施用时的毒性最小化。 为了靶向特定的细胞类型，纳米颗粒可以进一步与能够结合与特定细胞类型相关的细胞成分例如肿瘤标志物的配体缀合。 在一个实施方案中，治疗剂可以连接至纳米颗粒。 为了使纳米颗粒不仅可以通过光学荧光成像检测，而且可以通过其他成像技术如正电子发射断层摄影术（PET），单光子发射计算机断层摄影术（SPECT），计算机断层摄影术（CT），生物发光成像和磁共振 成像（MRI），放射性核素/放射性金属或顺磁性离子可以与纳米颗粒缀合。

    MULTIMODAL SILICA-BASED NANOPARTICLES
    3.
    发明公开
    MULTIMODAL SILICA-BASED NANOPARTICLES 审中-公开
    多模态硅基纳米粒子

    公开(公告)号：EP2968621A1

    公开(公告)日：2016-01-20

    申请号：EP14763612.0

    申请日：2014-03-17

    申请人： Sloan-Kettering Institute for Cancer Research ,  Cornell University

    发明人： BRADBURY, Michelle ,  WIESNER, Ulrich ,  PENATE MEDINA, Oula ,  BURNS, Andrew ,  LEWIS, Jason ,  LARSON, Steven ,  QUINN, Tom

    IPC分类号： A61K51/00 ,  A61B5/00 ,  A61K9/50 ,  G01N33/574

    CPC分类号： A61K51/1244 ,  A61K49/0002 ,  A61K49/0093 ,  G01N33/54346 ,  G01N33/552 ,  G01N33/574 ,  G01N33/582 ,  G01N33/587 ,  G01N33/60

    摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters, has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound, exhibits high biostability and biocompatibility, may be coated with an organic polymer, such as poly( ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. The nanoparticle may further be conjugated to a ligand. A therapeutic agent may be attached to the nanoparticle. Further, magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.

    摘要翻译： 本发明提供了荧光二氧化硅基纳米颗粒，其允许对诸如癌症的疾病的精确检测，表征，监测和治疗。 纳米粒子具有一定直径范围，具有位于纳米粒子内的荧光化合物，并且具有比游离荧光化合物更高的亮度和荧光量子产率，表现出高生物稳定性和生物相容性，可以用有机聚合物如聚（乙烯 乙二醇）（PEG）。 纳米颗粒的小尺寸，二氧化硅基质和有机聚合物涂层使纳米颗粒在体内施用时的毒性最小化。 纳米颗粒可以进一步与配体缀合。 治疗剂可以附着到纳米颗粒。 此外，磁共振成像（MRI），放射性核素/放射金属或顺磁性离子可以与纳米颗粒缀合。

    FLUORESCENT SILICA-BASED NANOPARTICLES
    4.
    发明公开
    FLUORESCENT SILICA-BASED NANOPARTICLES 审中-公开

    公开(公告)号：EP3499233A2

    公开(公告)日：2019-06-19

    申请号：EP19151874.5

    申请日：2010-07-02

    申请人： Sloan-Kettering Institute for Cancer Research ,  Cornell University

    发明人： BRADBURY, Michelle S. ,  WIESNER, Ulrich ,  PENATE MEDINA, Oula ,  OW, Hooisweng ,  BURNS, Andrew ,  LEWIS, Jason ,  LARSON, Steven

    IPC分类号： G01N33/50

    摘要： The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle.